期刊
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
卷 17, 期 2, 页码 111-130出版社
NATURE PORTFOLIO
DOI: 10.1038/s41575-019-0230-y
关键词
-
资金
- National Cancer Institute (NCI) of the NIH [CA72851, CA184792, CA202797, CA187956, CA214254]
- Cancer Prevention Research Institute of Texas [RP140784]
- Baylor Foundation
- Baylor Scott & White Research Institute
- Instituto de Salud Carlos III through the Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion [PI16/00766]
- European Regional Development Fund (ERDF)
- Instituto de Salud Carlos III
- Hospital Clinic's Premi Fi de Residencia
Epigenetic modifications and regulators, including DNA methylation, histone modifications and non-coding RNA species, have key pathophysiological roles in colorectal cancer (CRC). This Review outlines these epigenetic aberrations in CRC and their potential as diagnostic, prognostic and predictive biomarkers and therapeutic targets. Colorectal cancer (CRC), a leading cause of cancer-related death worldwide, evolves as a result of the stepwise accumulation of a series of genetic and epigenetic alterations in the normal colonic epithelium, leading to the development of colorectal adenomas and invasive adenocarcinomas. Although genetic alterations have a major role in a subset of CRCs, the pathophysiological contribution of epigenetic aberrations in this malignancy has attracted considerable attention. Data from the past couple of decades has unequivocally illustrated that epigenetic marks are important molecular hallmarks of cancer, as they occur very early in disease pathogenesis, involve virtually all key cancer-associated pathways and, most importantly, can be exploited as clinically relevant disease biomarkers for diagnosis, prognostication and prediction of treatment response. In this Review, we summarize the current knowledge on the best-studied epigenetic modifications in CRC, including DNA methylation and histone modifications, as well as the role of non-coding RNAs as epigenetic regulators. We focus on the emerging potential for the bench-to-bedside translation of some of these epigenetic alterations into clinical practice and discuss the burgeoning evidence supporting the potential of emerging epigenetic therapies in CRC as we usher in the era of precision medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据